Antiarrhythmic Effects of Spironolactone in Patients With ICDs
Status:
Completed
Trial end date:
2008-05-28
Target enrollment:
Participant gender:
Summary
This study will test whether spironolactone, an approved drug for among other things
hypertension, will reduce the risk of severe arrhythmias in patients with implanted
defibrillators. Half the patients in the study will get spironolactone and half will get a
placebo. Neither the patients or their providers will know if they are getting spironolactone
or placebo.